natgillin/translations-raw huggingface dataset:
De hyppigst observerede bivirkninger hos patienter behandlet med Gazyvaro var infusionsrelaterede reaktioner, der primært opstod under infusionen af de første 1000 mg.
The most frequently observed adverse drug reactions (ADRs) in patients receiving Gazyvaro were IRRs, which occurred predominantly during infusion of the first 1,000 mg.
De hyppigst observerede bivirkninger hos patienter, som fik MabThera var infusionsrelaterede reaktioner, som forekom hos de fleste patienter under første infusion.
The most frequently observed adverse drug reactions (ADRs) in patients receiving MabThera were IRRs which occurred in the majority of patients during the first infusion.
De hyppigst observerede bivirkninger hos patienter, som fik MabThera var infusionsrelaterede reaktioner, som hos de fleste patienter forekom under første infusion.
The most frequently observed adverse drug reactions (ADRs) in patients receiving MabThera were infusion-related reactions which occurred in the majority of patients during the first infusion.
De hyppigst observerede bivirkninger i kliniske forsøg med patienter, som fik olaparib-monoterapi (≥ 10 %), var kvalme, opkastning, diarré, dyspepsi, træthed, hovedpine, dysgeusi, nedsat appetit, svimmelhed, anæmi, neutropeni, lymfopeni, forhøjelse af middelcellevolumen og stigning i kreatinin.
The most frequently observed adverse reactions across clinical trials in patients receiving olaparib monotherapy (≥ 10%) were nausea, vomiting, diarrhoea, dyspepsia, fatigue, headache, dysgeusia, decreased appetite, dizziness, anaemia, neutropaenia, lymphopaenia, mean corpuscular volume elevation, and increase in creatinine.
De hyppigst observerede bivirkninger, der i studie MCL-002 opstod hyppigere i lenalidomidarmen end i kontrolarmen var neutropeni (50,9 %), anæmi (28,7 %), diarré (22,8 %), træthed (21,0 %), forstoppelse (17,4 %), pyreksi (16,8 %) og udslæt (herunder allergisk dermatitis) (16,2 %).
The most frequently observed adverse reactions which occurred more frequently in the lenalidomide arm compared with the control arm in Study MCL-002 were neutropenia (50.9%), anaemia (28.7%), diarrhoea (22.8%), fatigue (21.0%), constipation (17.4%), pyrexia (16.8%), and rash (including dermatitis allergic) (16.2%).
De hyppigst observerede bivirkninger, der i studie MCL-002 opstod hyppigere i lenalidomidarmen end i kontrolarmen, var neutropeni (50,9 %), anæmi (28,7 %), diarré (22,8 %), træthed (21,0 %), forstoppelse (17,4 %), pyreksi (16,8 %) og udslæt (herunder allergisk dermatitis) (16,2 %).
The most frequently observed adverse reactions which occurred more frequently in the lenalidomide arm compared with the control arm in Study MCL-002 were neutropenia (50.9%), anaemia (28.7%), diarrhoea (22.8%), fatigue (21.0%), constipation (17.4%), pyrexia (16.8%), and rash (including dermatitis allergic) (16.2%).
De hyppigst observerede lægemiddelbivirkninger (≥ 30 %) hos patienter, der får Stivarga, er asteni/træthed, hånd-fod-hudreaktion, diaré, nedsat appetit og fødeindtagelse, hypertension, dysfoni og infektion.
The most frequently observed adverse drug reactions (≥30%) in patients receiving Stivarga are asthenia/fatigue, hand foot skin reaction, diarrhoea, decreased appetite and food intake, hypertension, dysphonia and infection.
De hyppigst observerede maligniteter, når der ses bort fra ikke-melanom hudkræft, var prostatakræft, melanom, kolorektal kræft og brystkræft.
The most frequently observed malignancies, other than non-melanoma skin cancer, were prostate, melanoma, colorectal and breast cancers.
De hyppigst observerede resistensassocierede mutationer, der fremkom, omfattede L100I, K101E, V108I, E138K, V179F, Y181C, H221Y, F227C og M230I.
The most commonly observed resistance- associated mutations that emerged included L100I, K101E, V108I, E138K, V179F, Y181C, H221Y, F227C and M230I.
De hyppigst rapporterede
Most frequently reported are
De hyppigst rapporterede (set hos ≥ 1 % af patienter) bivirkninger, som blev set i forbindelsemed anvendelse af olanzapin i kliniske forsøg, var døsighed og vægtøgning, eosinofili, forhøjede niveauer af prolaktin, kolesterol, glucose og triglycerider (se pkt.
The most frequently (seen in ≥ 1 % of patients) reported adverse reactions associated with the use of
De hyppigst rapporterede (set hos ≥ 1 % af patienter) bivirkninger, som var forbundet med anvendelse af olanzapin i kliniske forsøg, var somnolens og vægtøgning, eosinofili, forhøjede niveauer af prolaktin, kolesterol, glucose og triglycerider (se pkt.
The most frequently (seen in ≥ 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin,
De hyppigst rapporterede bivirkninger (alle grader, ≥20 % forekomst) med mindst 2 % højere forekomst for ZALTRAP/FOLFIRI-regimet end for placebo/FOLFIRI-regimet var, med faldende frekvens: leukopeni, diarré, neutropeni, proteinuri, forhøjet aspartataminotransferase (ASAT), stomatitis, træthed, trombocytopeni, forhøjet alaninaminotransferase (ALAT), hypertension, vægttab, nedsat appetit, epistaxis, abdominalsmerter, dysfoni, forhøjet serumkreatinin og hovedpine (se Tabel 1).
The most common adverse reactions (all grades, ≥20% incidence) reported at least 2% greater incidence for the ZALTRAP/FOLFIRI regimen as compared to the placebo/FOLFIRI regimen in order of decreasing frequency were leucopenia, diarrhoea, neutropenia, proteinuria, increased aspartate aminotransferase (AST), stomatitis, fatigue, thrombocytopenia, increased alanine aminotransferase (ALT), hypertension, weight loss, decreased appetite, epistaxis, abdominal pain, dysphonia, increased serum creatinine, and headache (see Table 1).
De hyppigst rapporterede bivirkninger (der forekom hos ≥ 30 % af patienterne) er hypertension (68,6 %), diarré (62,8 %), nedsat appetit (51,5 %), vægttab (49,1 %), træthed (45,8 %), kvalme (44,5 %), proteinuri (36,9 %), stomatitis (35,8 %), opkastning (34,5 %), dysfoni (34,1 %), hovedpine (34,1 %) og palmar-plantar erytrodysæstesisyndrom (PPE) (32,7 %).
The most frequently reported adverse reactions (occurring in ≥30% of patients) are hypertension (68.6%), diarrhoea (62.8%), decreased appetite (51.5%), weight decreased (49.1%), fatigue (45.8%), nausea (44.5%), proteinuria 36.9%), stomatitis (35.8%), vomiting (34.5%), dysphonia (34.1%), headache (34.1%), and palmar-plantar erythrodysaesthesia syndrome (PPE) (32.7%).
De hyppigst rapporterede bivirkninger (forekommer hos > 10% af patienterne) er trombocytopeni, anæmi, pyreksi, hypertension, hypokaliæmi, hypofosfatæmi, urinvejsinfektion, hyperkolesterolæmi, hyperglykæmi, hypertriglyceridæmi, abdominalsmerter, lymfocele, perifert ødem, artralgi, akne, diarré, smerte, forstoppelse, kvalme, hovedpine, øget kreatinin i blodet og øget laktatdehydrogenase (LDH).
The most commonly reported adverse reactions (occurring in >10% of patients) are thrombocytopaenia, anaemia, pyrexia, hypertension, hypokalaemia, hypophosphataemia, urinary tract infection, hypercholesterolaemia, hyperglycaemia, hypertriglyceridaemia, abdominal pain, lymphocoele, peripheral oedema, arthralgia, acne, diarrhoea, pain, constipation, nausea, headache, increased blood creatinine, and increased blood lactate dehydrogenase (LDH).
De hyppigst rapporterede bivirkninger (incidens ≥ 10 % i INTELENCE-gruppen) uanset sværhedsgrad, der forekom i fase III-forsøgene, var udslæt (19,2 % i INTELENCE-gruppen versus 10,9 % i placebogruppen), diaré (18,0 % i INTELENCE-gruppen versus 23,5 % i placebogruppen), kvalme (14,9 % i INTELENCE-gruppen versus 12,7 % i placebogruppen) og hovedpine (10,9 % i INTELENCE-gruppen versus 12,7 % i placebogruppen).
The most frequently reported adverse drug reactions (ADRs) (incidence ≥ 10% in the INTELENCE arm) of all intensities occurring in the Phase III studies were rash (19.2% in the INTELENCE arm versus 10.9% in the placebo arm), diarrhoea (18.0% in the INTELENCE arm versus 23.5% in the placebo arm), nausea (14.9% in the INTELENCE arm versus 12.7% in the placebo arm) and headache (10.9% in the INTELENCE arm versus 12.7% in the placebo arm).
De hyppigst rapporterede bivirkninger (medicinrelateret behandling-fremkommende) i kombinationsbehandling (Caelyx + bortezomib) var kvalme (40 %), diarre (35 %), neutropeni (33 %), trombocytopeni (29 %), opkastning (28 %), træthed (27 %) og forstoppelse (22 %).
The most frequently reported (medicine-related treatment-emergent) adverse events in combination therapy (Caelyx + bortezomib) were nausea (40%), diarrhoea (35%), neutropaenia (33%), thrombocytopaenia (29%), vomiting (28%), fatigue (27%), and constipation (22%).
De hyppigst rapporterede bivirkninger (≤25 %) i de kontrollerede kliniske studier med Xiapex var penilt hæmatom, hævelse af penis og penissmerter.
The most frequently reported adverse drug reactions (≥25%) during the Xiapex controlled clinical studies were penile haematoma, penile swelling and penile pain.
De hyppigst rapporterede bivirkninger (≥ 10 % af patienter med SLE, der blev behandlet med Benlysta plus standardbehandling og som havde en hyppighed, der var  1 % større end placebo) var kvalme, diarré og feber.
The most frequently reported adverse reactions (≥10% of patient with SLE treated with Benlysta plus standard of care and at a rate ≥1% greater than placebo) were nausea, diarrhoea, and pyrexia.
De hyppigst rapporterede bivirkninger (≥5 %) var kvalme, overfølsomhedsreaktioner, reaktioner på infusionsstedet og hovedpine.
The most commonly reported adverse reactions (≥5%) were: nausea, hypersensitivity reactions, infusion site reactions, and headache.
De hyppigst rapporterede bivirkninger efter markedsføring, efter begge koncentrationer var godkendt, var brystsmerter, ansigtsrødme, blodtryksstigning og blodtryksfald, utilpashed, dyspnø, kvalme, opkastning, pyreksi, rygsmerter, hovedpine og kulderystelser.
The most reported post-marketing ADRs received since the product was authorised for both concentrations were chest pain, flushing, blood pressure increased and decreased, malaise, dyspnoea, nausea, vomiting pyrexia, back pain, headache and chills.
De hyppigst rapporterede bivirkninger efter Twinrix Voksen administreret efter 0, 1, 6 måneders standardprogrammet, er smerter og rødme med en frekvens pr. dosis på henholdsvis 37,6 % og 17,0 %.
The most commonly reported adverse reactions following Twinrix Adult administration with the standard 0, 1, 6 month schedule are pain and redness occurring in a per dose frequency of 37.6% and 17.0% respectively.
De hyppigst rapporterede bivirkninger er abdominal-smerter, som forekommer hos mere end 10 % af patienterne i de kliniske studier.
The most commonly reported adverse event is abdominal pain, occurring in more than 10% of patients in clinical trials.
De hyppigst rapporterede bivirkninger er hovedpine (11,5%), ødem/væskeretention (13,2% ), unormal leverfunktionstest (10,9%) og anæmi/fald i hæmoglobin (9,9%).
The most frequent adverse reactions are headache (11.5%), oedema/fluid retention (13.2%), abnormal liver function test (10.9%) and anaemia/haemoglobin decrease (9.9%).
De hyppigst rapporterede bivirkninger er hovedpine (11,5%), ødem/væskeretention (13,2%), unormal leverfunktionstest (10,9%) og anæmi/fald i hæmoglobin (9,9%).
The most frequent adverse reactions are headache (11.5%), oedema/fluid retention (13.2%), abnormal liver function test (10.9%) and anaemia/haemoglobin decrease (9.9%).
De hyppigst rapporterede bivirkninger er lokale reaktioner på injektionsstedet, f.eks. erythem, hævelse og kløe, som sædvanligvis er kortvarige af natur og milde i intensitet.
The most commonly reported side effects are local injection site reactions such as erythema, swelling and pruritus that are usually transient in nature and mild in intensity.
De hyppigst rapporterede bivirkninger er reaktioner på injektionsstedet (som smerte, hævelse. kløe, rødme og blødning på indstiksstedet), infektioner (som infektioner i de øvre luftveje, bronkitis, blærebetændelse og hudinfektioner), allergiske reaktioner, udvikling af autoantistoffer, kløe og feber.
The most commonly reported adverse reactions are injection site reactions (such as pain, swelling, itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections, bronchitis, bladder infections and skin infections), allergic reactions, development of autoantibodies, itching, and fever.
De hyppigst rapporterede bivirkninger er reaktioner ved injektionsstedet, asteni, kvalme og forhøjede leverenzymer (ALAT, ASAT, alkalisk fosfatase (ALP)).
The most frequently reported adverse reactions are injection site reactions, asthenia, nausea, and increased hepatic enzymes (ALT, AST, ALP).
De hyppigst rapporterede bivirkninger er svimmelhed og somnolens.
The most commonly reported adverse reactions were dizziness and somnolence.
De hyppigst rapporterede bivirkninger for Tasigna i kliniske studier
Most frequently reported adverse reactions in Tasigna clinical studies
De hyppigst rapporterede bivirkninger forbundet med indgift af SevoFlo var hypotension efterfulgt af takypnø, spændte muskler, eksitation, apnø, muskelfascikulationer og opkastning.
The most frequently reported adverse reactions associated with SevoFlo administration were hypotension, followed by tachypnoea, muscle tenseness, excitation, apnoea, muscle fasciculations and emesis.
De hyppigst rapporterede bivirkninger forbundet med indgift af Sevohale var hypotension efterfulgt af takypnø, spændte muskler, eksitation, apnø, muskelfascikulationer og opkastning.
The most frequently reported adverse reactions associated with Sevohale administration were hypotension, followed by tachypnoea, muscle tenseness, excitation, apnoea, muscle fasciculations and emesis.
De hyppigst rapporterede bivirkninger hos patienter med arthritis urica i kliniske forsøg (4.072 forsøgspersoner behandlet med doser fra 10 mg til 300 mg) og efter markedsføring er udbrud af arthritis urica, leverpåvirkning, diarre, kvalme, hovedpine, udslæt og ødem.
The most commonly reported adverse reactions in clinical trials (4,072 subjects treated at least with a dose from 10 mg to 300 mg) and post-marketing experience in gout patients are gout flares, liver function abnormalities, diarrhoea, nausea, headache, rash and oedema.
De hyppigst rapporterede bivirkninger hos patienter, som fik OZURDEX, var forhøjet intraokulært tryk (24,0 %) og konjunktivalblødning (14,7 %).
The most frequently reported adverse reactions in patients who received OZURDEX were increased intraocular pressure (24.0 %) and conjunctival haemorrhage (14.7 %).
De hyppigst rapporterede bivirkninger hos patienter, som har fået ritonavir alene eller i kombination med andre antiretrovirale lægemidler, er gastrointestinale (inklusive diarré, kvalme, opkastning, abdominalsmerter (øvre og nedre)), neurologiske forstyrrelser (inklusive paræstesi og oral paræstesi) samt træthed/asteni.
The most frequently reported adverse drug reactions among patients receiving ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paresthesia and oral paresthesia) and fatigue/asthenia.
De hyppigst rapporterede bivirkninger hos patienter, som har fået ritonavir alene eller i kombination med andre antiretrovirale lægemidler, er gastrointestinale (inklusive diarré, kvalme, opkastning, abdominalsmerter (øvre og nedre)), neurologiske forstyrrelser (inklusive paræstesi og oral paræstesi) samt træthed/asteni.
The most frequently reported adverse drug reactions among patients receiving ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhoea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paraesthesia and oral paraesthesia) and fatigue/asthenia.
De hyppigst rapporterede bivirkninger hos patienter, som tog CIALIS til behandling af erektil dysfunktion eller benign prostatahyperplasi, var hovedpine, dyspepsi rygsmerter og myalgi, hvor hyppigheden steg ved øget dosis af CIALIS.
The most commonly reported adverse reactions in patients taking CIALIS for the treatment of erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain and myalgia, in which the incidences increase with increasing dose of CIALIS.
De hyppigst rapporterede bivirkninger hos patienter, som tog Tadalafil Mylan til behandling af erektil dysfunktion eller benign prostatahyperplasi, var hovedpine, dyspepsi, rygsmerter og myalgi, hvor hyppigheden steg ved øget dosis af tadalafil.
The most commonly reported adverse reactions in patients taking tadalafil for the treatment of erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain and myalgia, in which the incidences increase with increasing dose of tadalafil.
De hyppigst rapporterede bivirkninger hos patienter, som tog tadalafil til behandling af erektil dysfunktion eller benign prostatahyperplasi, var hovedpine, dyspepsi rygsmerter og myalgi, hvor hyppigheden steg ved øget dosis aftadalafil.
The most commonly reported adverse reactions in patients taking tadalafil for the treatment of erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain and myalgia, in which the incidences increase with increasing dose of tadalafil.
De hyppigst rapporterede bivirkninger i de kliniske forsøg, der forekom hos  10% af de pegvisomant- behandlede akromegalipatienter, hovedpine 25%, artralgi 16% og diarré 13%.
The most commonly reported adverse reactions occurring in  10% of patients with acromegaly treated with pegvisomant during the clinical trials were headache 25%, arthralgia 16% and diarrhoea 13%.
De hyppigst rapporterede bivirkninger i de kliniske studier med voksne var hovedpine, søvnløshed, sedation/døsighed, parkinsonisme, akatisi, takykardi, tremor, dystoni infektion i de øvre luftveje, angst, svimmelhed, vægtøgning, kvalme, agitation, obstipation, opkastning, træthed, depression, dyspepsi, diarré, mundtørhed, tandpine, muskuloskeletale smerter, hypertension, asteni, rygsmerter, forlænget QT-interval i elektrokardiogrammet samt hoste.
The adverse drug reactions (ADRs) most frequently reported in clinical trials with adults were headache, insomnia, sedation/somnolence, parkinsonism, akathisia, tachycardia, tremor, dystonia, upper respiratory tract infection, anxiety, dizziness, weight increased, nausea, agitation, constipation, vomiting, fatigue, depression, dyspepsia, diarrhoea, dry mouth, toothache, musculoskeletal pain, hypertension, asthenia, back pain, electrocardiogram QT prolonged, and cough.
De hyppigst rapporterede bivirkninger i de kliniske studier med voksne var hovedpine, søvnløshed, sedation/døsighed, parkinsonisme, akatisi, takykardi, tremor, dystoni, infektion i de øvre luftveje, angst, svimmelhed, vægtøgning, kvalme, agitation, obstipation, opkastning, træthed, depression, dyspepsi, diarré, mundtørhed, tandpine, muskuloskeletale smerter, hypertension, asteni, rygsmerter, forlænget QT-interval i elektrokardiogrammet samt hoste.
The adverse drug reactions (ADRs) most frequently reported in clinical trials with adults were headache, insomnia, sedation/somnolence, parkinsonism, akathisia, tachycardia, tremor, dystonia, upper respiratory tract infection, anxiety, dizziness, weight increased, nausea, agitation, constipation, vomiting, fatigue, depression, dyspepsia, diarrhoea, dry mouth, toothache, musculoskeletal pain, hypertension, asthenia, back pain, electrocardiogram QT prolonged, and cough.
De hyppigst rapporterede bivirkninger i kliniske studier hos sildenafilbehandlede patienter var hovedpine, ansigtsrødme, dyspepsi, næsetilstopning, svimmelhed, kvalme, hedeture, synsforstyrrelser, cyanopsi (blåsyn) og sløret syn.
The most commonly reported adverse reactions in clinical studies among sildenafil treated patients were headache, flushing, dyspepsia, nasal congestion, dizziness, nausea, hot flush, visual disturbance, cyanopsia and. vision blurred.
De hyppigst rapporterede bivirkninger i kliniske studier med behandlingsnaive patienter, som fik emtricitabin+tenofoviralafenamid i kombination med elvitegravir+cobicistat, var kvalme (10 %), diarré (7 %) og hovedpine (6 %).
The most frequently reported adverse reactions in clinical studies of treatment-naïve patients taking emtricitabine+tenofovir alafenamide in combination with elvitegravir+cobicistat were nausea (10%), diarrhoea (7%), and headache (6%).
De hyppigst rapporterede bivirkninger i kliniske studier med behandlingsnaive patienter, som fik rilpivirinhydrochlorid i kombination med emtricitabin+tenofovirdisoproxilfumarat, var kvalme (9 %), svimmelhed (8 %), unormale drømme (8 %), hovedpine (6 %), diarré (5 %) og søvnløshed (5 %).
The most frequently reported adverse reactions in clinical studies of treatment-naïve patients taking rilpivirine hydrochloride in combination with emtricitabine+tenofovir disoproxil fumarate were nausea (9%), dizziness (8%), abnormal dreams (8%), headache (6%), diarrhoea (5%) and insomnia (5%).
De hyppigst rapporterede bivirkninger i kliniske studier til og med 96 uger var kvalme (10 %), diarré (7 %) og hovedpine (6 %) (samlede data fra de kliniske fase 3- studier GS-US-292-0104 og GS-US-292-0111 hos 866 behandlingsnaive voksne patienter, der fik Genvoya).
The most frequently reported adverse reactions in clinical studies through 96 weeks were nausea (10%), diarrhoea (7%), and headache (6%) (pooled data from Phase 3 clinical studies GS-US-292-0104 and GS-US-292-0111 in 866 treatment-naïve adult patients receiving Genvoya).
De hyppigst rapporterede bivirkninger i kliniske studier varede normalt kun en eller to dage og var ikke alvorlige.
The most common side effects reported during clinical trials usually lasted only one to two days and were not usually severe.
De hyppigst rapporterede bivirkninger i placebokontrollerede forsøg er akatisi og kvalme, som hver forekom hos mere end 3 % af de patienter, der blev behandlet med oral aripiprazol.
The most commonly reported adverse reactions in placebo-controlled trials are akathisia and nausea each occurring in more than 3 % of patients treated with oral aripiprazole.
De hyppigst rapporterede bivirkninger i placebokontrollerede forsøg er akatisi og kvalme, som hver forekom hos mere end 3 % af de patienter, der blev behandlet med oral Aripiprazole.
The most commonly reported adverse reactions in placebo-controlled trials are akathisia and nausea each occurring in more than 3% of patients treated with oral aripiprazole.
De hyppigst rapporterede bivirkninger i placebokontrollerede forsøg er kvalme, svimmelhed og døsighed, som alle forekom hos mere end 3 % af de patienter, der blev behandlet med aripiprazol injektionsvæske.
The most commonly reported adverse reactions in placebo-controlled trials are nausea, dizziness and somnolence each occurring in more than 3 % of patients treated with aripiprazole solution for injection.